#United States #San Diego #Robbins LLP #biotech #Regeneron

Robbins LLP Promotes Awareness for REGN Shareholders

Introduction

In a bid to protect shareholder rights, Robbins LLP has alerted investors of a recent class action lawsuit targeting Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This lawsuit pertains to claims about misleading business practices during the specified period from November 2, 2023, to October 30, 2024. As a biological product company known for its innovative treatments related to various diseases, Regeneron’s alleged actions have raised concerns among its shareholders.

The Allegations

According to the filed complaint, Robbins LLP outlines several key allegations against Regeneron during the class period. Notably, the company is accused of failing to disclose significant issues regarding its pricing strategies for Eylea, one of its leading products. Some crucial points raised in the complaint include:

1. Undisclosed Payment Arrangements: Regeneron allegedly provided financial incentives to distributors, ensuring they would not impose additional credit card usage fees on customers purchasing Eylea. These undisclosed payments effectively skewed the actual costs customers faced when acquiring the medication.
2. Price Manipulation: The lawsuit suggests that these practices allowed Regeneron to misleadingly represent its sales figures for Eylea, inflating the perceived success of the drug in the marketplace. By not accurately reporting the payment of credit card fees, the true average selling price (ASP) was overstated, resulting in potential violations of the False Claims Act.
3. Misleading Financial Stability: The conveyed perceptions about Regeneron's robust business operations, which flourished on the alleged successful sales of Eylea, were greatly misleading. When these practices became public knowledge, Regeneron's stock price dropped significantly, directly impacting investors.

The Path Forward for Shareholders

Shareholders of Regeneron Pharmaceuticals who wish to be a part of this class action can submit their applications by March 4, 2025, to serve as lead plaintiffs. The role of a lead plaintiff involves representing fellow affected shareholders in the litigation process. However, it’s important to note that investors do not necessarily need to take legal action to remain eligible for potential recovery.

Robbins LLP operates on a contingency fee basis, which means that shareholders will incur no extra costs unless there’s a recovery in the case. This setup ensures that shareholders can seek justice without financial strain.

About Robbins LLP

With a long-standing commitment to defending shareholder rights since 2002, Robbins LLP is dedicated to helping investors recover from losses incurred due to corporate misconduct. Their track record of holding executives accountable reinforces their esteemed position within the shareholder advocacy community.

Conclusion

The current class action offers an important opportunity for REGN shareholders to seek recompense for potential losses. It’s crucial for investors affected by Regeneron’s alleged misreporting to stay informed and consider participating in the suit. For updates and further information regarding the progress of the case, shareholders can reach out to Robbins LLP directly or sign up for notifications.

Link to complete details about the class action can be found through Robbins LLP’s official site. Together, shareholders can navigate the challenges posed by corporate misrepresentation and pursue justice through collective action.